Thymopentin – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

Thymopentin is a 5-amino-acid synthetic peptide representing the active region of thymopoietin. Used historically for psoriasis and immune modulation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A mature thymic pentapeptide with real approvals but overshadowed by thymosin alpha-1 across every meaningful axis

Look, thymopentin is a legitimate compound. Arg-Lys-Asp-Val-Tyr, five residues that happen to capture most of thymopoietin’s functional activity in a peptide you can synthesize cleanly and administer subcutaneously. It’s approved in Italy under the Timunox brand, approved in China and several other Asian markets for primary immunodeficiency and hepatitis B support, and has been used in clinical practice for decades. That’s not nothing. The compound is real, the mechanism is real, the human data is real.

The problem is context. When you look at where the thymic peptide space actually sits today, thymopentin is the compound you consider before you remember that thymosin alpha-1 exists. Zadaxin has broader regulatory approval, a more extensive multi-center trial base, better-characterized cytokine kinetics, and a cleaner reputation in the literature. If youre building a research program around thymic biology and T-cell maturation, thymopentin isnt where you start. It’s where you end up if thymosin alpha-1 is unavailable or if you have a specific reason to work with the thymopoietin fragment specifically.

The mechanism is genuinely interesting in principle: the compound appears to promote thymocyte maturation, modulates the CD4/CD8 ratio, and has documented NK cell effects. We don’t dismiss that. But the biology here is well-trodden 1980s immunopharmacology. The trials supporting its approvals predate modern RCT standards. Most of the published literature comes from the era when open-label studies in Eastern European and Asian centers were the standard of evidence, and replication across independent Western lab groups is thin.

What we find most limiting is the differentiation story. The thymic peptide category has a clear hierarchy, and thymopentin isn’t at the top. Thymosin alpha-1 outperforms it on evidence density, indication breadth, and regulatory reach. Thymosin beta-4 fragments occupy a different but increasingly interesting niche. Thymopentin sits in the middle: approved, real, known, but not best-in-class on any axis that matters for a serious research prioritization decision in 2025.

There is some bench value here. If you’re specifically investigating the thymopoietin receptor axis, or studying the minimal active fragment hypothesis in thymic hormone biology, thymopentin is the obvious probe. The five-residue sequence is well-defined and commercially available from reputable peptide vendors, which matters for reproducibility. We think this is where its research merit is most defensible: as a structural probe for a well-mapped biology, not as a frontier target. Honest assessment puts it in the established-mature bucket, useful but not urgent, and a distant second to the compounds that have pushed this field forward more recently.

Novelty: 32
Mechanism promise: 38
In-category differentiation: 25
Evidence quality: 48
Translational signal: 52
Research bench value: 40

Rationale Thymopentin has genuine regulatory standing in Italy and several Asian markets, which pushes evidence and translational scores above peptides stuck in preclinical purgatory, but it sits squarely behind thymosin alpha-1 on differentiation and behind newer immunomodulatory targets on novelty. The thymic peptide biology is real and the pentapeptide design is elegant, but this is 1980s-era pharmacology competing in a field that has moved on.

Synthetic pentapeptide of thymopoietin

A synthetic pentapeptide fragment (residues 32-36) of thymopoietin marketed in Europe and Asia for immunomodulation in chronic infections and autoimmune disease.

Abstract

Thymopentin (Timunox, TP-5; Arg-Lys-Asp-Val-Tyr; CAS 69558-55-0; molecular weight 679.78) is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, a thymic hormone. The fragment retains the immunomodulatory activity of full-length thymopoietin. The compound is approved in Italy and several Asian countries for primary immunodeficiency, hepatitis B, atopic dermatitis adjunct, and autoimmune disease support. Mechanism includes T-cell maturation, NK cell modulation, and cytokine balance effects. Administered subcutaneously. Doses are 50 mg three times weekly in clinical use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-130Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.